# OnCo record nct05890742 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05890742/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05890742", "NCT05890742" ;
  schema:name "A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer"@en ;
  schema:description "A phase 3 trial of Sintilimab in colorectal cancer, run by Innovent Biologics (Suzhou) Co. Ltd., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05890742/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05890742> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2023-05-25" ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/msi-high-colorectal/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/sintilimab/> ;
  onco:companies <https://onco.cc/companies/innovent/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct05890742-cancer-cell-2025/> .